Loss of expression of tuberin and hamartin in tuberous sclerosis complex-associated but not in sporadic angiofibromas

Journal of Cutaneous Pathology

Volumn 30, Issue 3, 2003, Pages 174-177

  Fackler, Ingrid ^a   DeClue, Jeffrey E ^b   Rust, Heidi ^a   Vu, Phuong Anh ^a   Kutzner, Heinz ^c   Rütten, Arno ^c   Kaddu, Steven ^d   Sander, Christian A ^a   Volkenandt, Matthias ^a   Johnson, Michael W ^e   Vinters, Harry V ^e   Wienecke, Ralf ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Dermatopathologische Gemeinschaftspraxis   (Germany)

^d UNIVERSITY OF GRAZ   (Austria)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAMARTIN; PROTEIN ANTIBODY; TUBERIN;

ANTIBODY AFFINITY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE MUTATION; HEMANGIOFIBROMA; HETEROZYGOSITY LOSS; HISTIOCYTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIUM; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SKIN BLOOD VESSEL; SKIN FIBROBLAST; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR GENE;

ANGIOFIBROMA; HUMANS; IMMUNOHISTOCHEMISTRY; PROTEINS; REPRESSOR PROTEINS; SKIN NEOPLASMS; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 0037359426     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0560.2003.2o066.x     Document Type: Article

References (28)

1. Webb DW, Clarke A, Fryer A, Osborne JP. The cutaneous features of tuberous sclerosis: a population study. Br J Dermatol 1996; 135: 1.
2. Darling TN, Skarulis MC, Steinberg SM, et al. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol 1997; 133: 853.
3. Rogers RSI. Dermatologic Manifestations. In: Gomez MR, ed. Tuberous Sclerosis. New York: Raven Press, 1988; 111.
4. Sanchez NP, Wick MR, Perry HO. Adenoma sebaceum of Pringle: a clinicopathologic review. J Cut Pathol 1981; 8: 395.
5. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 1998; 13: 624.
6. O'Callaghan FJ, Shiell AW, Osborne JP, Martyn CN. Prevalence of tuberous sclerosis estimated by capture-recapture analysis [letter] [see comments]. Lancet 1998; 351: 1490.
7. Northrup H, Wheless JW, Bertin TK, Lewis RA. Variability of expression in tuberous sclerosis. J Med Genet 1993; 30: 41.
8. Slegtenhorst Mv de Hoogt R, Hermans C, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277: 805.
9. The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993; 75: 1305.
10. Jones AC, Daniells CE, Snell RG, et al. Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis. Hum Mol Genet 1997; 6: 2155.
11. Slegtenhorst Mv Nellist M, Nagelkerken B, Nagelkerken B, et al. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 1998; 7: 1053.
12. Johnson MW, Emelin JK, Park SH, Vinters HV. Co-localization of TSC1 and TSC2 gene products in tubers of patients with tuberous sclerosis. Brain Pathol 1999; 9: 45.
13. Plank TL, Logginidou H, Klein-Szanto A, Henske EP. The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1- and TSC2-linked angiomyolipomas. Mod Pathol 1999; 12: 539.
14. Plank TL, Yeung RS, Henske EP. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res 1998; 58: 4766.
15. Jin F, Wienecke R, Xiao GH, et al. Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region. Proc Natl Acad Sci U S A 1996; 93: 9154.
16. Carbonara C, Longa L, Grosso E, et al. Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas. Genes Chromosomes Cancer 1996; 15: 18.
17. Green AJ, Smith M, Yates JR. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat Genet 1994; 6: 193.
18. Henske EP, Neumann HP, Scheithauer BW, et al. Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosomes Cancer 1995; 13: 295.
19. Sepp T, Yates JR, Green AJ. Loss of heterozygosity in tuberous sclerosis hamartomas. J Med Genet 1996; 33: 962.
20. Wienecke R, Maize JC Jr, Shoarinejad F, et al. Co-localization of the TSC2 product tuberin with its target Rap1 in the Golgi apparatus. Oncogene 1996; 13: 913.
21. Wienecke R, Guha A, Maize JR, et al. Reduced TSC2 RNA and protein in sporadic astrocytomas and ependymomas. Ann Neurol 1997; 42: 230.
22. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32: 219.
23. Nguyen-Vu PA, Fackler I, Rust A, et al. Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis. J Cutan Pathol 2001; 28: 470.
24. Pack S, Turner ML, Zhuang Z, et al. Cutaneous tumors in patients with multiple endocrine neoplasia type 1 show allelic deletion of the MEN1 gene. J Invest Dermatol 1998; 110: 438.
25. Niida Y, Stemmer-Rachamimov AO, Logrip M, et al. Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet 2001; 69: 493.
26. Vortmeyer AO, Boni R, Pack SD, Darling TN, Zhuang Z. Perivascular cells harboring multiple endocrine neoplasia type 1 alterations are neoplastic cells in angiofibromas. Cancer Res 1999; 59: 274.
27. Benvenuto G, Li S, Brown SJ, et al. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 2000; 19: 6306.
28. Mizuguchi M, Ikeda K, Takashima S. Simultaneous loss of hamartin and tuberin from the cerebrum, kidney and heart with tuberous sclerosis. Acta Neuropathol (Berl) 2000; 99: 503.